PermeaDerm accelerates early wound healing in partial-thickness burns: A multicenter randomized controlled trial

Area of Science:

• Regenerative Medicine
• Dermatology
• Biomaterials Science

Background:

• A multicenter, randomized controlled trial assessed PermeaDerm, a biosynthetic wound matrix, against porcine acellular dermal matrix (ADM).
• The study focused on the safety and efficacy of these matrices for treating partial-thickness burns in Chinese patients.

Purpose of the Study:

• To compare the efficacy and safety of PermeaDerm versus ADM in treating partial-thickness burns.
• To evaluate PermeaDerm's potential as an alternative wound management option.

Main Methods:

• 184 Chinese patients with partial-thickness burns were randomized to receive either PermeaDerm or ADM.
• Primary endpoint: proportion of wounds achieving complete re-epithelialization by day 14 (superficial) or 21 (deep).
• Secondary endpoints included healing rates, wound area reduction, pain, and complication incidence.

Main Results:

• PermeaDerm was non-inferior to ADM for the primary endpoint.
• Significantly higher early re-epithelialization rates and wound area reduction were observed with PermeaDerm on day 7 for both burn types.
• PermeaDerm shortened the time to complete re-epithelialization by 3 days, with similar safety profiles and improved ease of application.

Conclusions:

• PermeaDerm accelerates early wound healing and reduces overall healing time for partial-thickness burns.
• The biosynthetic matrix demonstrated a comparable safety profile to ADM.
• PermeaDerm presents a clinically valuable alternative for managing partial-thickness burns.